skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: assunto: Humans remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Models for the modern power grid
Models for the modern power grid
Material Type:
Artigo 		Adicionar ao Meu Espaço

Models for the modern power grid

Cardieri, Paulo, 1964- Universidade Estadual de Campinas (Unicamp); Universidade Estadual De Campinas

https://repositorio.unicamp.br/acervo/detalhe/1191204

2014

Acesso online

2
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
Material Type:
Artigo 		Adicionar ao Meu Espaço

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

Deodhar, A ; Mease, P J ; McInnes, I B ; Baraliakos, X ; Reich, K ; Blauvelt, A ; Leonardi, C ; Porter, B ; Das Gupta, A ; Widmer, A ; Pricop, L ; Fox, T

Arthritis research & therapy, 2019-05, Vol.21 (1), p.111-11, Article 111 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por
3
Cutaneous melanoma: From pathogenesis to therapy (Review)
Cutaneous melanoma: From pathogenesis to therapy (Review)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Cutaneous melanoma: From pathogenesis to therapy (Review)

Leonardi, Giulia C ; Falzone, Luca ; Salemi, Rossella ; Zanghi, Antonino ; Spandidos, Demetrios A ; Mccubrey, James A ; Candido, Saverio ; Libra, Massimo

International journal of oncology, 2018-04, Vol.52 (4), p.1071-1080

Athens: Spandidos Publications

Texto completo disponível

Citações Citado por
4
Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)
Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)

Papp, K. ; Menter, A. ; Leonardi, C. ; Soung, J. ; Weiss, S. ; Pillai, R. ; Jacobson, A.

British journal of dermatology (1951), 2020-12, Vol.183 (6), p.1037-1048 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
5
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)

Bissonnette, R. ; Luger, T. ; Thaçi, D. ; Toth, D. ; Lacombe, A. ; Xia, S. ; Mazur, R. ; Patekar, M. ; Charef, P. ; Milutinovic, M. ; Leonardi, C. ; Mrowietz, U.

Journal of the European Academy of Dermatology and Venereology, 2018-09, Vol.32 (9), p.1507-1514 [Periódico revisado por pares]

England: John Wiley and Sons Inc

Texto completo disponível

Citações Citado por
6
Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR)
Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR)

Blauvelt, A. ; Ferris, L.K. ; Yamauchi, P.S. ; Qureshi, A. ; Leonardi, C.L. ; Farahi, K. ; Fakharzadeh, S. ; Hsu, M.‐C. ; Li, S. ; Chevrier, M. ; Smith, K. ; Goyal, K. ; Chen, Y. ; Muñoz‐Elías, E.J. ; Callis Duffin, K.

British journal of dermatology (1951), 2017-12, Vol.177 (6), p.1552-1561 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
7
Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies

Strober, B. ; Menter, A. ; Leonardi, C. ; Gordon, K. ; Lambert, J. ; Puig, L. ; Photowala, H. ; Longcore, M. ; Zhan, T. ; Foley, P.

Journal of the European Academy of Dermatology and Venereology, 2020-12, Vol.34 (12), p.2830-2838 [Periódico revisado por pares]

England: John Wiley and Sons Inc

Texto completo disponível

Citações Citado por
8
Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up
Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up
Material Type:
Artigo 		Adicionar ao Meu Espaço

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

Papp, K.A. ; Lebwohl, M.G. ; Puig, L. ; Ohtsuki, M. ; Beissert, S. ; Zeng, J. ; Rubant, S. ; Sinvhal, R. ; Zhao, Y. ; Soliman, A.M. ; Alperovich, G. ; Leonardi, C.

British journal of dermatology (1951), 2021-12, Vol.185 (6), p.1135-1145 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
9
Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
Material Type:
Artigo 		Adicionar ao Meu Espaço

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method

Mrowietz, U. ; Warren, R.B. ; Leonardi, C.L. ; Saure, D. ; Petto, H. ; Hartz, S. ; Dossenbach, M. ; Reich, K.

Journal of the European Academy of Dermatology and Venereology, 2021-05, Vol.35 (5), p.1161-1175 [Periódico revisado por pares]

England: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
10
Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)
Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)

Kimball, A.B. ; Leonardi, C. ; Stahle, M. ; Gulliver, W. ; Chevrier, M. ; Fakharzadeh, S. ; Goyal, K. ; Calabro, S. ; Langholff, W. ; Menter, A.

British journal of dermatology (1951), 2014-07, Vol.171 (1), p.137-147 [Periódico revisado por pares]

Oxford: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (650)
  2. Revistas revisadas por pares (599)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (647)
  2. Anais de Congresso  (3)
  3. magazinearticle  (1)
  4. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1986  (22)
  2. 1986Até1994  (62)
  3. 1995Até2003  (117)
  4. 2004Até2013  (260)
  5. Após 2013  (224)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (636)
  2. Japonês  (66)
  3. Italiano  (21)
  4. Francês  (2)
  5. Alemão  (2)
  6. Português  (1)
  7. Indeterminado  (1)
  8. Espanhol  (1)
  9. Mais opções open sub menu

Novas Pesquisas Sugeridas

Ignorar minha busca e procurar por tudo

Deste Autor:

  1. Godoy, I
  2. Campana, Á
  3. Staut, L
  4. Silva, F
  5. Junqueira, V

Neste Assunto:

  1. Humans
  2. Humans
  3. Science & Technology
  4. Life Sciences & Biomedicine
  5. Female

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.